Literature DB >> 23582100

An in silico virtual screening study for the design of norovirus inhibitors: fragment-based molecular docking and binding free energy calculations.

Magnus Lundborg1, Eunus Ali, Göran Widmalm.   

Abstract

Gastrointestinal infections caused by noroviruses may be prevented by the inhibition of their binding to histo-blood group carbohydrate antigens. A fragment-based virtual screening approach was used, employing docking followed by molecular dynamics simulations in order to enable binding free energy calculations using the linear interaction energy method. The resulting structures, composed of high-affinity fragments, can be a good starting point for lead optimizations and four molecules that pass both REOS and SYLVIA filters, which can remove known toxic features and assess the synthetic accessibility, respectively, are proposed as inhibitors.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Caliciviridae; Carbohydrate antigen; In silico screening; Influenza; Ro3; Scoring function

Mesh:

Substances:

Year:  2013        PMID: 23582100     DOI: 10.1016/j.carres.2013.03.012

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  3 in total

Review 1.  Current tools for norovirus drug discovery.

Authors:  Sahani Weerasekara; Allan M Prior; Duy H Hua
Journal:  Expert Opin Drug Discov       Date:  2016-05-02       Impact factor: 6.098

Review 2.  Norovirus drug candidates that inhibit viral capsid attachment to human histo-blood group antigens.

Authors:  Eunüs S Ali; Harinda Rajapaksha; Jillian M Carr; Nikolai Petrovsky
Journal:  Antiviral Res       Date:  2016-07-13       Impact factor: 5.970

3.  A Lead-Based Fragment Library Screening of the Glycosyltransferase WaaG from Escherichia coli.

Authors:  Federico Riu; Alessandro Ruda; Olof Engström; Claudio Muheim; Hani Mobarak; Jonas Ståhle; Paul Kosma; Antonio Carta; Daniel O Daley; Göran Widmalm
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.